Baseline tumour measurements predict survival in advanced non-small cell lung cancer

D. E. Gerber; S. E. Dahlberg; A. B. Sandler; D. H. Ahn; J. H. Schiller; J. R. Brahmer; D. H. Johnson

doi:10.1038/bjc.2013.472

Baseline tumour measurements predict survival in advanced non-small cell lung cancer

D. E. Gerber, S. E. Dahlberg, A. B. Sandler, D. H. Ahn, J. H. Schiller, J. R. Brahmer, D. H. Johnson

Hematology/Oncology

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Background:The association between tumour measurements and survival has been studied extensively in early-stage and locally advanced non-small cell lung cancer (NSCLC). We analysed these factors in patients with advanced NSCLC.Methods:Data were derived from the E4599 trial of paclitaxel-carboplatin±bevacizumab. Associations between the Response Evaluation Criteria in Solid Tumors (RECIST) baseline sum longest diameter (BSLD), response rate, progression-free survival (PFS) and overall survival (OS) were evaluated using univariate and multivariable Cox regression models.Results:A total of 759 of the 850 patients (89%) in the E4599 trial had measurable diseases and were included in this analysis. The median BSLD was 7.5 cm. BSLD predicted OS (hazard ratio (HR) 1.41; P<0.001) and had a trend towards association with PFS (HR 1.14; P=0.08). The median OS was 12.6 months for patients with BSLD <7.5 cm compared with 9.5 months for BSLD ≥7.5 cm. This association persisted in a multivariable model controlling multiple prognostic factors, including the presence and sites of extrathoracic disease (HR 1.24; P=0.01). There was no association between BSLD and response rate.Conclusion:Tumour measurements are associated with survival in the E4599 trial. If validated in other populations, this parameter may provide important prognostic information to patients and clinicians.

Original language	English (US)
Pages (from-to)	1476-1481
Number of pages	6
Journal	British journal of cancer
Volume	109
Issue number	6
DOIs	https://doi.org/10.1038/bjc.2013.472
State	Published - Sep 17 2013

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/bjc.2013.472

Cite this

@article{963b7caba392488ebb2c8e04fcdd5550,

title = "Baseline tumour measurements predict survival in advanced non-small cell lung cancer",

abstract = "Background:The association between tumour measurements and survival has been studied extensively in early-stage and locally advanced non-small cell lung cancer (NSCLC). We analysed these factors in patients with advanced NSCLC.Methods:Data were derived from the E4599 trial of paclitaxel-carboplatin±bevacizumab. Associations between the Response Evaluation Criteria in Solid Tumors (RECIST) baseline sum longest diameter (BSLD), response rate, progression-free survival (PFS) and overall survival (OS) were evaluated using univariate and multivariable Cox regression models.Results:A total of 759 of the 850 patients (89%) in the E4599 trial had measurable diseases and were included in this analysis. The median BSLD was 7.5 cm. BSLD predicted OS (hazard ratio (HR) 1.41; P<0.001) and had a trend towards association with PFS (HR 1.14; P=0.08). The median OS was 12.6 months for patients with BSLD <7.5 cm compared with 9.5 months for BSLD ≥7.5 cm. This association persisted in a multivariable model controlling multiple prognostic factors, including the presence and sites of extrathoracic disease (HR 1.24; P=0.01). There was no association between BSLD and response rate.Conclusion:Tumour measurements are associated with survival in the E4599 trial. If validated in other populations, this parameter may provide important prognostic information to patients and clinicians.",

author = "Gerber, {D. E.} and Dahlberg, {S. E.} and Sandler, {A. B.} and Ahn, {D. H.} and Schiller, {J. H.} and Brahmer, {J. R.} and Johnson, {D. H.}",

note = "Funding Information: This study was conducted by the Eastern Cooperative Oncology Group (Robert L Comis, MD) and supported in part by the Public Health Service Grant CA23318 from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. This work was also supported by a National Cancer Institute Cancer Clinical Investigator Team Leadership Award (1P30 CA142543-01 supplement) (to DEG) and the North and Central Texas Clinical and Translational Science Initiative (NCTCTSI) (KL2RR024983) (to DEG). The contents of this study are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.",

year = "2013",

month = sep,

day = "17",

doi = "10.1038/bjc.2013.472",

language = "English (US)",

volume = "109",

pages = "1476--1481",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Baseline tumour measurements predict survival in advanced non-small cell lung cancer

AU - Gerber, D. E.

AU - Dahlberg, S. E.

AU - Sandler, A. B.

AU - Ahn, D. H.

AU - Schiller, J. H.

AU - Brahmer, J. R.

AU - Johnson, D. H.

N1 - Funding Information: This study was conducted by the Eastern Cooperative Oncology Group (Robert L Comis, MD) and supported in part by the Public Health Service Grant CA23318 from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. This work was also supported by a National Cancer Institute Cancer Clinical Investigator Team Leadership Award (1P30 CA142543-01 supplement) (to DEG) and the North and Central Texas Clinical and Translational Science Initiative (NCTCTSI) (KL2RR024983) (to DEG). The contents of this study are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

PY - 2013/9/17

Y1 - 2013/9/17

N2 - Background:The association between tumour measurements and survival has been studied extensively in early-stage and locally advanced non-small cell lung cancer (NSCLC). We analysed these factors in patients with advanced NSCLC.Methods:Data were derived from the E4599 trial of paclitaxel-carboplatin±bevacizumab. Associations between the Response Evaluation Criteria in Solid Tumors (RECIST) baseline sum longest diameter (BSLD), response rate, progression-free survival (PFS) and overall survival (OS) were evaluated using univariate and multivariable Cox regression models.Results:A total of 759 of the 850 patients (89%) in the E4599 trial had measurable diseases and were included in this analysis. The median BSLD was 7.5 cm. BSLD predicted OS (hazard ratio (HR) 1.41; P<0.001) and had a trend towards association with PFS (HR 1.14; P=0.08). The median OS was 12.6 months for patients with BSLD <7.5 cm compared with 9.5 months for BSLD ≥7.5 cm. This association persisted in a multivariable model controlling multiple prognostic factors, including the presence and sites of extrathoracic disease (HR 1.24; P=0.01). There was no association between BSLD and response rate.Conclusion:Tumour measurements are associated with survival in the E4599 trial. If validated in other populations, this parameter may provide important prognostic information to patients and clinicians.

AB - Background:The association between tumour measurements and survival has been studied extensively in early-stage and locally advanced non-small cell lung cancer (NSCLC). We analysed these factors in patients with advanced NSCLC.Methods:Data were derived from the E4599 trial of paclitaxel-carboplatin±bevacizumab. Associations between the Response Evaluation Criteria in Solid Tumors (RECIST) baseline sum longest diameter (BSLD), response rate, progression-free survival (PFS) and overall survival (OS) were evaluated using univariate and multivariable Cox regression models.Results:A total of 759 of the 850 patients (89%) in the E4599 trial had measurable diseases and were included in this analysis. The median BSLD was 7.5 cm. BSLD predicted OS (hazard ratio (HR) 1.41; P<0.001) and had a trend towards association with PFS (HR 1.14; P=0.08). The median OS was 12.6 months for patients with BSLD <7.5 cm compared with 9.5 months for BSLD ≥7.5 cm. This association persisted in a multivariable model controlling multiple prognostic factors, including the presence and sites of extrathoracic disease (HR 1.24; P=0.01). There was no association between BSLD and response rate.Conclusion:Tumour measurements are associated with survival in the E4599 trial. If validated in other populations, this parameter may provide important prognostic information to patients and clinicians.

UR - http://www.scopus.com/inward/record.url?scp=84884586658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884586658&partnerID=8YFLogxK

U2 - 10.1038/bjc.2013.472

DO - 10.1038/bjc.2013.472

M3 - Article

C2 - 23942074

AN - SCOPUS:84884586658

SN - 0007-0920

VL - 109

SP - 1476

EP - 1481

JO - British journal of cancer

JF - British journal of cancer

IS - 6

ER -

Baseline tumour measurements predict survival in advanced non-small cell lung cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this